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To determine whether the long-term reduction of preload and
afterload by captopril during healing after acute anterior myocar-
dial infarction might attenuate left ventricular remodeling and
improve function, 30 chronically instrumented dogs with infarc-
tion produced by left anterior descending coronary artery ligation
were randomized 2 days later to oral therapy with placebo (n =
15) or captopril, 50 mg twice daily (n =15), for 6 weeks. Serial
hemodynamic as well as topographic and functional variables
(two-dimensional echocardiography) were measured over 6 weeks.
Scar topography (planimetry), occluded bed size (coronary arte-
riography) and collagen (hydroxyproline) content were measured
at 6 weeks.
Between 2 days r .;:; 6 weeks, captopril decreased (p < 0.001)
mean arterial pressure and mean left atrial pressure more than
did placebo, but it did not influence heart rate. Infarct scar mass,
transmurality and collagen content at 6 weeks were similar in the
Healing after acute myocardial infarction takes place over a
protracted period during which profound and progressive
alterations in architecture and shape occur and influence
function. The duration of healing averages 15 weeks (range
6 to 24) in humans (1), 6 weeks in dogs and 3 weeks in rats
(2). In the canine model, healing is associated with progres-
sive left ventricular remodeling, with early infarct expansion
and cavity dilation in the 1st week when inflammation
predominates and with late thinning between 3 and 6 weeks
when collagen deposition predominates (2-4). Hydroxypro-
line, a marker for collagen, increases substantially in the
infarct zone after 7 days, reaches a peak level between 3and
6 weeks, undergoes transmural compaction and results in
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two groups but scars showed less (p < 0.001) thinning and
expansion with captopril than with placebo. Echocardiograms
showed similar infarct expansion and thinning in the two groups
at 2 days but less aneurysm with captopril at 6 weeks. Be-
tween 2 days and 6 weeks, expansion index (infarct-/noninfarct-
containing segment length) decreased (p < 0.001) with captopril
but increased (p < 0.001) with placebo. Also, thinning ratio
(infarct/normal wall thickness) decreased (p < 0.001) with placebo
but did not change (p =NS) with captopril.
By 6 weeks, left ventricular asynergy and volumes showed a
greater decrease (p < 0.01) and global ejection fraction a greater
increase (p < 0.05) with captopril. Thus, captopril therapy during
healing after canine anterior infarction limits left ventricular
remodeling and improves left ventricular function.
(J Am Coli CardioI1992;19:713-21)
marked infarct wall thinning (2-4). Thus, collagen deposited
in already expanded and thinned infarct segments appears to
fix the topographic deformation during healing, resulting in
aneurysm formation and heart failure that contribute to late
morbidity and mortality in survivors of acute infarction (2).
During the healing period, the infarct segment is exposed
to various mechanical deformation forces (such as preload,
afterload, heart rate and contractility) that contribute in a
dynamic fashion to topographic changes and remodeling
(5,6). Very early therapies applied during the infarction
process to limit infarct size and decrease preload and after-
load have been shown to limit early remodeling (7,8) and
improve outcome and survival (8). The effect of long-term
reduction of preload and afterload during healing after the
infarction process is completed has not been studied system-
atically in the canine model. Recent interest has focused on
activation of the renin-angiotensin-aldosterone system dur-
ing acute myocardial infarction (9) and on the ability of the
angiotensin-converting enzyme inhibitor captopril to de-
crease preload and afterload by arterial and venous dilation
(10,11) and its potential for limiting ventricular remodeling
during the healing period and improving function (12). Stud-
ies (13) in the rat model have shown that long-term captopril
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therapy for 3 months after coronary ligation attenuates left
ventricular dilation and deterioration of performance.
The purpose of this study was to determine whether
prolonged reduction of preload and afterload by long-term
captopril therapy, applied after completion of myocardial
infarction and during the subsequent healing process, can
prevent further infarct expansion and late thinning and
improve left ventricular function in the canine model. Serial
changes in remodeling and function during healing were
measured by quantitative two-dimensional echocardiog-
raphy (8,14-16).
Methods
All experiments conformed to the "Position of the Amer-
ican Heart Association on Research Animal Use" adopted
by the Association on November 11, 1984.
Experimental preparation. Fifty healthy male or female
mongrel dogs (16 to 22 kg) were fitted with instruments
through a left lateral thoracotomy under general anesthesia
(sodium pentobarbital, 30 mg/kg body weight intravenously),
as described previously (2-4,7). Polyethylene catheters were
inserted in the external jugular vein, internal carotid artery
and left atrium, filled with heparinized saline solution and
their ends exteriorized behind the neck, A silk ligature was
placed around the left anterior descending coronary artery,
distal to the first diagonal branch, and tied. Metal beads were
sutured on the anterior, lateral and posterior epicardial
surfaces in the short-axis plane at the mid-left ventricular
level for consistent echocardiographic orientation for serial
topography. The pericardium and chest were then closed,
penicillin (1 million U) and streptomycin (1 g) were given
intramuscularly and the dogs returned to their cages. At 6
weeks, the dogs were anesthetized and the heart was ar-
rested in diastole with an overdose of intravenous potassium
chloride, excised, washed in normal saline solution and
weighed.
Protocol. Forty-eight hours after coronary artery liga-
tion, the 42 healthy survivors were randomized to 6weeks of
oral therapy with captopril (50 mg twice daily, n = 21) or
placebo (n = 21). The dogs were allowed free access to fluids
and no attempt was made to treat heart failure by fluid
restriction or pharmacotherapy.
Serial recordings during healing. As described previously
(2,3), serial electrocardiograms (EeGs) (Gould pen record-
er), hemodynamic variables (Statham P23Db transducer for
left atrial and arterial pressures) and two-dimensional
echocardiograms (Toshiba SSH-65A echocardiograph;
3.5 MHz transducer) were recorded over eight time intervals
with the dogs in the conscious state, standing in a sling for
support: preoperatively, at 2 days and weekly for 6 weeks
after coronary ligation. Echocardiograms were stored on 0.5
in. (1.27 cm) VHS videotape for later analysis. In human
studies (14,15), the views included five parasternal short-axis
views from base to apex at mitral, chordal, mid-papillary,
low papillary and apical levels; the parasternal long-axis
Figure 1. Postmortem coronary arteriograms to determine occluded
bed size. A, Schematic showing method of ligation of the mid-left
anterior descending coronary artery (LAD), the occluded bed (stip-
pled) and transverse sections (broken line). LC = left circumflex
coronary artery. B, Radiograph of a postmortem arteriogram visu-
alizing epicardial and transmural vessels. C, Transverse sections of
left ventricular rings showing the infarcted anterior wall in rings
from base to apex in a 7-day old infarct. The right ventricle was
removed. D, Radiograph ofa transverse section with markings (solid
black lines) of the occluded bed across the wall.
view and the apical four- and two-chamber views. Blood
samples were taken for monitoring blood gases, hemograms
and serum electrolytes. Venous plasma renin and aldoste-
rone levels were measured (preoperatively and at 2days and
6 weeks) in selected dogs by radioimmunoassay (17).
Measurement of scar size and geometry. At 6 weeks,
postmortem coronary arteriography (Fig. 1) was performed
on the fresh heart with use of simultaneous pressure-
controlled injections of all coronary arteries with a mixture
of barium sulfate and gelatin as described previously (2). The
heart was then fixed in distension (15 cm pressure head) to
preserve diastolic proportions with 10% phosphate-buffered
formalin solution for 48 h and radiographed in two perpen-
dicular planes. Five transverse sections (1 to I.5 cm thick),
with four equally spaced sections below the level of the
ligation to the apex, were then made and radiographed.
Boundaries of the occluded bed were marked on section
radiographs (Fig. ID) by consensus of two observers at the
watersheds between terminal branches of the visualized
vessels (2). The sections were weighed after removal of the
right ventricle and other extraneous tissue, materials and
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beads. Outlines of the rings, occluded zone and infarct scar
were made on plastic overlays.
Computerized planimetry (Hewlett-Packard 9835A com-
puter and 9874A digitizer interfaced with a VAX 750 com-
puter) was used to derive the following variables, as de-
scribed previously (2): areas of the ring and cavity, infarct
scar, occluded bed and noninfarcted myocardium; thick-
nesses of infarct and left ventricular ring; endocardial
lengths of infarct and noninfarct segments; circumferences
of the ring and infarct; mass of infarct and occluded bed by
relating the average areas (top and bottom surfaces) to the
weight of each ring; total masses of infarct and occluded bed
for each heart by summing values for each ring; "thinning"
ratio (ratio of average thickness of infarct wall to average
thickness ofthe normal wall); and "expansion" index (ratio
of endocardial lengths of infarct- to noninfarct-containing
segments demarcated by papillary muscle landmarks); and
transmurality index (average of ratio of the maximal thick-
ness of the infarct and left ventricular wall from all infarcted
rings, expressed as percent). Average maps were computed
for each group.
Histology. Histopathologic studies were performed on a
5-mm slice from the middle of the infarct zone. Three 5-JLm
thick sections were stained, respectively, with hematoxylin-
eosin, Mallory stain or Masson trichrome stain and exam-
ined for infarct scar and collagen.
Determination of total hydroxyproline content. As de-
scribed previously (2,7), transmural myocardial tissue sam-
ples were taken from the center, border and margin regions
of the infarct scar and the center of the nonoccluded bed,
weighed (100 to 200 mg) and processed for measurement of
hydroxyproline content, as a marker for collagen, in mg/g
dry tissue weight.
Analysis of echocardiograms. Coded echocardiograms
were analyzed on video playback in double-blind fashion by
two independent observers (B.I.1. and B.L.S.-M. or M.I.K.)
at the end of the studies, as described previously (8.14-16).
Briefly, endocardial and epicardial outlines of the left ven-
tricular images at end-diastole and end-systole were traced
with a light pen (Quantic 1200 review station, Franklin),
corrected on to and fro playback over at least three consec-
utive cycles and copied on plastic overlays. Anatomic land-
marks (papillary muscle; right and left ventricular junctions)
were indicated on the tracings. Markings of asynergy, de-
fined as akinesia (no systolic inward motion and thickening)
or dyskinesia (systolic outward motion and thinning), or
both, were made on each endocardial diastolic outline by
careful visual assessment of motion and thickening on re-
peated video playbacks. The circumferential extents on each
short-axis view were then digitized (Hewlett-Packard mod-
els 9878A and 9835A) and used to compute total asynergy.
Outlines from five short-axis and two long-axis views were
used to compute volumes by means of the modified Simp-
son's rule (8).
Global ejection fraction was calculated as (End-diastolic
volume - End-systolic volume)/End-diastolic volume. The
interobserver error was <5% in marking asynergy, segment
length, wall thickness and areas of outlines, in agreement
with previous studies (8,14-16). Topographic measurements
were made on end-diastolic outlines of short-axis images at
the papillary level, as on the postmortem heart.
Expansion index was computed as the ratio of the lengths
of the segments containing asynergic and nonasynergic
zones. Thinning ratio was computed as the ratio of the
average thicknesses of the asynergic and nonasynergic
zones. Regional area ejection fraction was calculated at the
same level as (End-diastolic area - End-systolic area)/End-
diastolic area. The degree of regional bulging in the asyner-
gic zone was characterized by its depth (rct), as described
previously (14,16). Left ventricular aneurysm was defined as
the presence of a diastolic bulge with further bulging and
thinning in systole.
Statistics. Data at different steps were coded and ana-
lyzed in blinded fashion at the end. The following statistical
tests were used: 1) analysis of variance for the significance of
difference within and between groups; 2) linear regression
analysis by the least squares fit method, and the significance
of r values and slopes by analysis of variance; 3) 2 x 2
chi-square and Fisher exact tests for the significance of
difference in event frequency between groups; and 4) re-
peated measures analysis of variance for comparing serial
data within groups. Results are presented as mean values ±
SD. Statistical significance was set at p < 0.05.
Results
The two study groups. Of the 50 dogs that underwent
mid-left anterior descending coronary artery ligation, 8
(16%) died before randomization at 48 hours. Ten more dogs
(20%), five from each group, died between 2 days and 6
weeks after randomization. Of the 32 dogs that were killed at
6 weeks, 1 from each group had no histologic evidence of
infarct scar, and was excluded from analysis. Serial hemo-
dynamic, topographic and functional data over 6 weeks as
well as final pathologic data at 6 weeks are presented for the
30 dogs that had infarction and survived 6 weeks (15 in the
placebo, 15 in the captopril group). These final groups were
comparable with respect to age (2.3 vs. 2 years), gender
(40% vs. 60% male), initial body weight (20 vs. 21 kg), final
body weight (19 vs. 20 kg) and interval to induced death
(44 vs, 44 days).
Hemodynamic changes. Heart rate. Over the 6 weeks,
there was no difference in heart rate between the two groups
but, compared with placebo, captopril produced a prompt
and persistent decrease in mean left atrial pressure and mean
arterial pressure (Fig. 2). Thus, in the captopril and placebo
groups, mean heart rate was similar preoperatively (117 ±
21 vs. 116 ± 18 beats/min), at 2 days (136 ± 19 vs. 131 ±
22 beats/min) and at 6 weeks (87 ± 11 vs. 87 ± 13 beats/min).
Heart rate decreased similarly between 2 days and 6 weeks
in the two groups (percent change - 38 ± 12% vs. - 34 ±
18%, respectively),
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Figure 2. Effect of captopril on hemodynamics. Left panel, Changes
over eight time intervals from preocclusion (PRE-OCCL) to 6
weeks. P values for significance of difference between 2days and 6
weeks obtained by multiple measures analysis of variance. Right
panel, Percent changes. p values obtained by analysis of variance.
Left atrial pressure. In contrast, mean left atrial pressure
(Fig. 2) was similar in the captopril and placebo groups
preoperatively (5.6 ± 1.1 vs. 5.4 ± 0.7 mm Hg) and at 2days
(12.7 ± 2.1 vs. 13.6 ± 2.6 mm Hg) but was markedly less
with captopril between 1 week (7.6 ± 2.6 vs. 13.5 ±
5.2 mm Hg, p < 0.(01) and 6 weeks (5.9 ± 1.9 vs. 10.4 ±
2.9 mm Hg, p < 0.(01). The percent decrease in left atrial
pressure between 2 days and 6 weeks was greater with
captopril (-52 ± 18 vs. -23 ± 19%, P < 0.001).
Arterial pressure. Also, mean arterial pressure (Fig. 2)
was similar in the captopril and placebo groups preopera-
tively (114 ± 12 vs. 110 ± 7 mm Hg) and at 2 days (117 ± 12
vs. 111 ± 14 mm Hg) but was less with captopril between
1 and 6 weeks. Values at 2 and 6 weeks were 97 ± 11 vs.
111 ± 18 mm Hg (p < 0.025) and 98 ± 12 vs. III ± 9 mm Hg
(p < 0.005), respectively. The percent decrease in mean
arterial pressure between 2 days and 6 weeks was greater
with captopril (-15 ± 12 vs. +1 ± 13%, P < 0.005). This
decrease in mean arterial pressure was reflected in decreases
in both systolic and diastolic pressures, values at 6 weeks
being 131 ± 18 vs. 148 ± 18 mm Hg (p < 0.025) for systolic
and 83 ± 10 vs. 96 ± 11 mm Hg (p < 0.005) for diastolic
pressure, respectively.
The rate-pressure product. The rate-pressure product
(mean arterial pressure x heart rate) in the captopril and
placebo groups was similar at 2 days (159 ± 20 vs. 145 ± 30
beats/min x mm Hg x 102, P < 0.05) but less at 6 weeks (86
± 19 vs. 97 ± 14 beats/min x mm Hg x 102, P < 0.05). The
percent change in rate-pressure product between 2 days and
6weeks was greater with captopril than with placebo (-46 ±
12 vs. -31 ± 12%, p < 0.005).
Infarct scar size. The mass of the infarct scar was similar
(p == NS) in the captopril and control groups (6.4 ± 3.5 vs.
5.7 ± 2.7 g) relative to left ventricular mass (8.3 ± 4.5 vs. 9 ±
Table 1. Topographic Measurements on Infarct Scar at
6Weeks in 30 Dogs
Placebo Captopril p
(n = 15) (n = 15) Value
Area of scar (cm2) 2.6 ± 1.8 2.4 ± 2.1 NS
Circumference of scar (em) 6.7 ± 2.6 6.0 ± 4.2 NS
Endocardial scar segment (em) 3.4 ± 1.5 0.9 ± 1.6 0.001
Area of scar/left ventricle (%) 20.5 ± 9.7 17.7 ± 13.3 NS
Maximal transmural extent of 91 ± 15 90 ± 20 NS
scar (%)
Thickness of scar (mm) 6.8 ± 2.4 9.1 ± 2.7 0.025
Thickness of normal wall (mm) 11.4 ± 2.3 11.1 ± 1.7 NS
Thickness ratio 0.59 ± 0.13 0.82 ± 0.17 0.001
Area of inner LV ring (cm2) 5.3 ± 2.0 3.7 ± 2.6 0.01
Circumference of inner LV ring 8.2 ± 1.8 6.8 ± 2.1 0.01
(cm)
Area of outer LV ring (cm2) 15.7 ± 4.2 17.2 ± 3.6 NS
Circumference of outer LV ring 13.8 ± 2.1 14.8 ± 1.5 NS
(cm)
Area of LV tissue (cm2) 12.5 ± 3.5 13.8 ± 2.5 NS
Area of normal tissue (cm2) 9.9 ± 2.9 11.4 ± 3.1 NS
Normal endocardIal segment (cm) 4.8 ± 1.3 5.9 ± 1.7 0.05
Scar segment length (cm) 6.1 ± 0.9 4.6 ± I 0.001
Nonscar segment length (cm) 2.2 ± 0.2 2.2 ± 0.2 NS
Expansion index 2.8 ± 0.4 2.0 ± 0.4 0.001
LV = left ventricular.
4.5%) or to occluded bed mass (43.1 ± 18.6 vs. 48.6 ±
15.2%). The mass of the left ventricle (78.4 ± 13.2 vs. 66.7 ±
13.9 g) and occluded bed (15.4 ± 5.6 vs. 12.2 ± 5.1 g) was
also similar in the two groups. Similar and significant linear
correlations were present between scar mass and occluded
bed mass in the captopril (y == O.64x - 4.41, r == 0.81, SEE ==
4.88, n == 15, P < 0.(01) and placebo (y == 0.82x - 4.06, r ==
0.96, SEE == 2.94, n == 15, p < 0.001) groups, with no
difference in the slopes. Histopathologic study showed sim-
ilar scar tissue at 6 weeks with variable epicardial rims of
normal tissue in both groups.
Scar morphology and left ventricular topography after
healing. Eighteen main topographic measurements from the
mid-left ventricular region of the infarcted heart at 6 weeks
are summarized for the two groups in Table 1. There was no
difference between the placebo and captopril groups in the
area of the infarct scar (21% vs. 18% left ventricle), the
average maximal transmural extent of the scar (91% vs. 90%)
and area of normal myocardium (12.5 vs. 13.8 cm2). In
contrast, there was evidence of more expansion of the
infarct scar in the placebo than in the captopril group as
indicated by a longer endocardial scar segment (3.4 vs.
0.9 em, p < 0.001), a longer endocardial scar segment length
(6.1 vs. 4.6 em, p < 0.(01), a larger expansion index (2.8 vs.
2, p < 0.001) and a larger cavity area (5.3 vs. 3.7 cm2, p <
0.01). In addition, there was more thinning in the placebo
than in the captopril group as indicated by a thinner scar
(6.8 vs. 9.1 mm, p < 0.025) and lower thickness ratio
(0.59 vs. 0.82, P < 0.001).
The computer-generated average geometric maps from
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PLACEBO (n=15)
Figure 4. Effect of captopril on infarct expansion. Format and
abbreviations as in Figure 2.
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Figure 5. Effect of captopril on infarct thinning. Format and abbre-
viations as in Figure 2.
groups, the expansion indexes being 2.27 and 2.34, respec-
tively. However, between 2 days and 6 weeks after infarc-
tion, expansion index increased with placebo (2.27 ± 0.24
vs. 2.87 ± 0.39, p < 0.001) but decreased with captopril
(2.34 ± 0.27 VS. 1.87 ± 0.16, P < 0.001). The expansion
index was less in the captopril than in the placebo group as
early as 1 week (2.25 ± 0.34 vs. 2.49 ± 0.28, P < 0.05) and
this beneficial effect was even more marked by 6 weeks
(1.87 ± 0.16 vs. 2.87 ± 0.39, p < 0.001). The percent change
in expansion index between 2 days and 6 weeks with
captopril was markedly different from that with placebo
(-19 ± 11% vs. +26 ± 17%, p < 0.001). These changes were
associated with a decrease in the infarct-containing endocar-
dial segment length (Fig. 4) with captopril and an increase
with placebo (-12 ± 16% vs. +47 ± 31%, p < 0.0005). In
addition, the increase in noninfarct-containing endocardial
segment length was less with captopril than with placebo
(+9 ± 11% vs. + 18 ± 9%, p < 0.025).
Similar degrees of thinning (Fig. 5) had occurred on
echocardiograms by 2 days in both the placebo and the
captopril group (thickness ratio 0.8 ± 0.12 vs. 0.82 ± 0.12).
Between 2 days and 6 weeks, the thickness ratio decreased
further with placebo (0.8 ± 0.12 vs. 0.61 ± 0.1, P < 0.001)
but did not change with captopril (0.82 ± 0.12 vs. 0.83 ±
0.07, p = NS). The percent change in thickness ratio over
that interval was greater with placebo than with captopril
(-24 ± 7% vs. +3 ± 19%, P < 0.0005). The percent change
in infarct thickness was also greater with placebo (-22 ±
13% vs. +16 ± 20%, p < 0.0005). The difference in thinning
between the two groups was more marked between 3 and
6 weeks.
Thus, compared with the placebo group, the captopril
group showed higher thickness ratios at 3weeks (0.83 ± 0.07
vs. 0.69 ± 0.13, p < 0.005), 4 weeks (0.83 ± 0.08 VS. 0.65 ±
0.11, p < 0.001), 5 weeks (0.83 ± 0.08 vs. 0.63 ± O.l, p <
0.001) and 6 weeks (0.83 ± 0.07 vs. 0.61 ± 0.1, P < 0.001).
These changes were associated with marked late thinning of
the infarct scar between 2 weeks and 6 weeks, with a
decrease in thickness from 0.71 ± 13 em at 1week to 0.68 ±
1.0 [ ~ I I= I i ~
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Figure 3. Effect of captopril on infarct scar topography. Computer-
generated average maps of infarct scars and risk regions in trans-
verse left ventricular sections from base (left) to apex (right) for the
two treatment groups at 6 weeks. Points are at 5° angular intervals.
Anterior (A) and posterior (P) junctions between right and left
ventricles are indicated. The maps with captopril show less defor-
mation, angular extent (0) in degrees and thickness of the infarct
scar than do those with placebo.
all five left ventricular rings from base to apex for the two
groups are depicted in Figure 3. The angular extents of the
scar (0), in degrees, in the infarct rings were slightly greater
in the placebo than in the captopril group: ring 2,30 :t 21 VS.
13 :t 19; ring 3, 119 ± 36 vs. 88 ± 35; ring 4, 162 ± 34 vs.
128 ± 37; and ring 5, 171 ± 38 vs. 137 ± 39. The thickness
of the mid-infarct wall was greater (p < 0.0005) in the
captopril than in the placebo group: ring 2, 1.08 ± 0.11 vs.
0.92 ± 0.07 em; ring 3, 0.91 ± 0.08 vs. 0.68 ± 0.07 cm; ring
4, 0.85 ± 0.1 VS. 0.62 ± 0.11 cm; ring 5, 0.88 ± 0.11 vs.
0.62 ± 0.09 cm. The noninfarct wall thickness was not
significantly different in the two groups. However, the cavity
area was slightly less with captopril than with placebo (p <
0.05).
Changes in left ventricular topography during healing.
Similar degrees of expansion (Fig. 4) had occurred on
echocardiograms by 2 days in the placebo and captopril
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Figure 6. Effect of captopril on left ventricular dilation and function.
Format as in Figure 2. LV == left ventricular; other abbreviation as
in Figure 2.
Placebo Captopril
Region (n = 15) (n = 15)
Normal zone 5.3 ± 1.3 5.3 ± 1.0
Infarct border 11.9±6.7 12.1 ± 6.2
Infarct margm 23.7 ± 11.3 20.5 ± 14.2
Infarct center 34 ± 10.7* 29.2 ± 14.5*
Discussion
Four major findings in this study. Remodeling during
healing after canine infarction. First, healing during the 1st
6 weeks after acute anterior myocardial infarction in the
canine model was associated with progressive left ventricu-
lar remodeling manifested by early infarct expansion, late
thinning, frequent aneurysm formation and persistent ven-
*p ~ 0.05 compared with values in other regions within the group.
Table 2. Effect of Captopril on Regional Hydroxyproline Content
(mg/g dry weight)
End-systolic volume (Fig. 6) also increased equally by
2 days in the placebo and control groups to 50 and 49 ml,
respectively. Between 2 days and 6 weeks, it increased
slightly with placebo (50 ± 14 vs. 53 ± 14 ml, p < 0.01) but
decreased markedly with captopril (49 ± 9 vs. 29 ± 10 ml,
p < 0.0005). Thus, systolic volume at 6 weeks was markedly
smaller with captopril than with placebo (29 vs. 53 ml, p <
0.0005). The percent change in systolic volume between
2 days and 6 weeks was greater with captopril than with
placebo (-39 ± 18 vs. +8 ± 23%, P < 0.0005).
The changes in volumes and global ejection fraction were
associated with concordant changes in areas and regional
area ejection fraction.
Scar collagen. There was a similar gradient in myocardial
hydroxyproline content, a marker for collagen, across the
infarct scar in the placebo and captopril groups, with higher
values in the infarct center than in infarct border and margin
zones (Table 2). However, there was no difference in re-
gional collagen content of the infarct scar or normal myo-
cardium in the two groups.
Plasma renin and aldosterone. Preoperative venous
plasma renin (1.4 ± 0.9 vs. 1.6 ± 0.7 ng/ml per h) and
aldosterone (197 ± 141 vs. 142 ± 82 pmol/Iiter) from five
dogs in each group were similar (p = NS). These levels
increased (p ::s 0.05) after coronary occlusion in both the
placebo and captopril groups: renin, 3.5 ± 1.1 vs. 4.1 ±
1.2 ng/ml per h, respectively; aldosterone, 450 ± 292 vs.
510 ± 216 pmoUliter, respectively. Between postocclusion
measurement and 6 weeks, captopril resulted in a marked
increase in plasma renin (4.1 ± 1.2 vs. 7.5 ± 2.9 ng/ml per h,
p < 0.05) and a decrease in plasma aldosterone (510 ± 216
vs. 14 ± 26 pmol/liter, p < 0.005). At 6 weeks, plasma renin
was higher (7.5 ± 2.9 vs. 2.9 ± 1.3 ng/ml per h, p < 0.025)
and aldosterone was lower (14 ± 26 vs. 149 ± 100 pmol/liter,
p < 0.025) with captopril than with placebo.
........ CAPTOPRIL.
TOTAL LV ASYNERGY ( .. )
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0.14 cm at 2 weeks and 0.57 ± 11 cm at 6 weeks (Fig. 5). The
thickness of the noninfarct wall did not change significantly
between 2 days and 6 weeks, the percent change being +5 ±
8% with placebo and +3 ± 6% with captopril (p = NS).
Aneurysmal bulging at 6 weeks was more frequent with
placebo than with captopri/: 11 of 15 (73%) vs. 0 of 15.
chi-square value = 14.35, P < 0.0005; p =0 by Fisher exact
test. The depth of diastolic bulge at the mid-papillary level
was also less with captopril (0.3 ± 0.1 vs. 2.4 ± 1.9 mm, p <
0.001).
Changes in left ventricular function during infarct healing.
Total left ventricular asynergy (Fig. 6), an index of regional
contractile function, was similar in placebo and captopril
groups at 2 days (14 ± 5 vs. 13 ± 5%, p = NS). It decreased
between 2 days and 6 weeks in both the placebo (14 ± 5 vs.
11 ± 4%, P < 0.01) and the captopril (13 ± 5 vs. 7 ± 4%, p <
0.001) group, but the percent decrease was greater with
captopril (-50 ± 23 vs. -18 ± 24%, P < 0.001).
Global left ventricular ejection fraction (Fig. 6), an index
of global systolic contractile function or performance, was
similarly depressed in the placebo and captopril groups at
2 days (39 ± 6 vs. 41 ± 7%, P = NS). It improved between
2 days and 6 weeks in both the placebo (39 ± 6 vs. 44 ± 7%,
P < 0.001) and the captopril (41 ± 7 vs. 56 ± 10%, P <
0.0005) group, but the percent increase was greater with
captopril (+ 15 ± 22 vs. 36 ± 18%, p < 0.01). At 6 weeks,
ejection fraction was greater with captopril than with pla-
cebo (56 ± 10 vs. 44 ± 7%, p < 0.005).
End-diastolic volume (Fig. 6) had increased equally in the
placebo and captopril groups by 2 days to 82.5 and 83.8 ml,
respectively. Between 2 days and 6 weeks, it continued to
increase in the placebo group (82.5 ± 17.7 vs. 93.3 ± 17.0 ml,
p < 0.001), but it decreased in the captopril group (83.8 ±
14.8 vs. 67.5 ± 9.8 ml, p < 0.001). The diastolic volume at
6 weeks was therefore greater with placebo than with
captopril (93.3 vs. 67.5 ml, p < 0.0005). The percent change
in diastolic volume was also greater with captopril than with
placebo (-18 ± 16 vs. + 14 ± 14%, P < 0.0005).
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tricular dysfunction as demonstrated by serial two-
dimensional echocardiography.
Effect of captopril on remodeling and function. Second,
long-term captopril therapy between 2 days and 6 weeks
after infarction limited left ventricular remodeling in the dog
model. This effect was manifested by a prevention of further
early infarct expansion, a lack of late thinning, less diastolic
bulging, abolition ofaneurysms, and marked improvement in
regional and global systolic function.
Left ventricular unloading and angiotensin-converting
enzyme inhibition. Third, these beneficial effects of capto-
pril were associated with sustained decreases in preload and
afterload but no change in heart rate. Thus, left atrial
pressure, a measure of preload decreased by 40% to 53%
from the baseline level during the 6 weeks of captopril
therapy. Also, mean arterial pressure, a measure of after-
load, decreased by 12% to 18% from the baseline level
during captopril therapy. Evidence of pharmacologic effect
was confirmed by the finding of increased plasma renin and
decreased aldosterone with captopril.
Infarct size, transmurality and collagen. Fourth, these
beneficial effects of captopril were not due to limitation of
infarct size, differences in infarct transmurality or collagen
content of the infarct scar. Therapy was begun 2 days after
coronary artery ligation, by which time the infarction pro-
cess is completed. Infarct scar mass, transmurality and
collagen content were similar in the captopril and placebo
groups at 6 weeks.
Critique of the model. Histopathologic evaluation of tem-
poral changes in left ventricular topography during healing
after acute myocardial infarction was previously performed
in this model but required groups of dogs to be killed at
different times over 6 weeks (2). In the present study, the
ability of quantitative two-dimensional echocardiography,
by systematic tomographic imaging, to serially follow
changes in left ventricular dysfunction (18) and topography
(3,4,19) during postinfarction healing in vivo, with each
subject acting as its own biologic control, was exploited to
document that attenuation of the temporal changes in left
ventricular remodeling has a positive effect on left ventricu-
lar function.
Special precautions were taken in quantifying remodel-
ing. Postmortem variables were all measured at 6 weeks on
hearts that were arrested in diastole and fixed under similar
distending pressure. Echocardiographic variables were mea-
sured at eight time intervals over 6 weeks in all dogs, in the
conscious state, with the pericardium closed, and at the
same short-axis level.
The echocardiographic approach has been used exten-
sively in our laboratory for the detailed and accurate quan-
titation of left ventricular remodeling in experimental and
clinical settings (3,4,8,14-16,20). Since the quality of two-
dimensional echocardiographic images is superior in dogs
than in humans, this model of postinfarction healing is
particularly suitable for applying echocardiographic tech-
niques in studying interventions to limit left ventricular
remodeling and preserve function.
A requirement for the serial measurements after acute
anterior infarction was survival of the dogs to 6 weeks. This
was achieved in this study by using a lower or mid-left
anterior descending coronary artery ligation which resulted
in an infarct of appreciable size at the cost of an acceptable
mortality rate of 36%. As a trade-off, the infarct scar at 6
weeks was small, averaging 9% of left ventricular mass
(range 3% to 18.3%). This observation is in agreement with
data from previous reports (2-4,7) using large numbers of
dogs. Because the infarct scar contracts during healing over
6 weeks, an infarct with a mean size of 19% at 1 day after
coronary occlusion is roughly equivalent to a size of 14% at
1week and 10% at 6weeks, as shown in a previous study (2)
where the occluded bed was similar in size.
Although the infarct scar was small in the present study,
several points should be emphasized. 1) The average trans-
mural extent of the scar at 6 weeks was 91%for the placebo
and 90% for the captopril group. 2) The infarct scar showed
evidence of substantial early expansion and late thinning,
and the left ventricular systolic and diastolic dimensions
showed significant progressive dilatation and aneurysm for-
mation. Thus, comparing the baseline preocclusion values
with the values at 6 weeks in the placebo group, the
expansion index (Fig. 5) increased by 68% (from 1.71 to 2.87)
and the thickness ratio (Fig. 6) decreased by 35% (from 0.88
to 0.57). In a canine study of anterior and inferior infarcts
between 1 to 11 days old, Eaton and Bulkley (21) found
expansion regularly in transmural infarcts > 11% of the left
ventricle in size. 3) The magnitude and duration of the
stimulus for compensatory hypertrophy in the placebo group
might have been insufficient in view of the small infarct scar
size despite evidence of left ventricular dilation, as noted
previously with this model (2). 4) The total abolition of left
ventricular aneurysm with captopril therapy might be in part
explained by the fact that the infarct scars were "relatively"
small.
Clinical relevance. There is general agreement that mod·
erate to large anterior transmural infarcts show more early
expansion and therefore are subject to greater remodeling
during healing (8,12,15,16,19,22). Since an epicardial rim of
normal myocardium appears to provide a buttress against
early expansion (21), the severity of expansion might have
been greater if the infarcts had been 100% transmural
throughout their longitudinal and transverse extents. Al-
though some of the dogs that died before 6 weeks had a
larger infarct (0% to 39%), their data on left ventricular
geometry and function could not be included in the analysis
as they did not span over the 6 weeks. In the 1990s, the
majority of patients will have benefited from early throm-
bolytic therapy and other infarct-limiting therapies in the 1st
48 h. The findings in this study indicate that further remod-
eling occurs after completion of the infarction process and
that this can be attenuated by chronic therapy. The results
therefore provide a rationale for treating survivors of acute
720 JUGDUTI ET AL.
CAPTOPRIL AND VENTRICULAR REMODELING AFTER INFARCTION
lACC Vol. 19. No.3
March 1. 1992:713-21
myocardial infarction to prevent further topographic deteri-
oration during healing and to improve left ventricular func-
tion.
Determinants of remodeling. Three major determinants
of left ventricular remodeling after infarction (5,6) are rec-
ognized: 1) physical characteristics of the infarct, especially
infarct size and transmurality; 2) adequacy of the healing
process influenced mainly by the inflammatory component,
fibroblast proliferation and collagen deposition, nutrient flow
during healing, and metabolic and cellular factors; and
3) mechanical deformation forces such as preload, afterload,
contractility, heart rate, wall stress and tension.
Previous studies in the dog model. Whether captopril
reduces infarct size and decreases transmurality is contro-
versial (10,23,24). Using an anesthetized dog model, Ertl et
al. (23) found that early therapy with intravenous captopril
(0.25 mg/kg per h) during the infarction process, between
30 min and 6 h after left anterior descending coronary artery
occlusion, decreased infarct size by 31%. This effect was
associated with a 62% increase in collateral blood flow as
well as a 10% decrease in mean arterial pressure (from 115 to
105 mm Hg) and a 37% decrease in mean left atrial pressure
(from 9 to 5.7 mm Hg). In contrast, Liang et al. (10), using a
salt-supplemented conscious dog model of left anterior de-
scending coronary artery occlusion, found no effect on
infarct size when early but more prolonged angiotensin-
converting enzyme inhibition therapy was used. In that
study (10), intravenous teprotide (25 jLg/kg per min) was
begun at 40 min after occlusion and followed by captopril
(10 mg/kg) every 8 h for 24 h. Although teprotide decreased
peripheral vascular resistance by 24% and mean aortic
pressure by 9%, increased cardiac output by 19% and
increased renal and splanchnic flow, there was no effect on
left atrial pressure, segmental systolic shortening, myocar-
dial blood flow or infarct size. It is possible that the large
dose of captopril used by Liang et al. (10), 10 mg/kg or
200 mg every 8 h for a 20-kg dog, might have caused
excessive hypotension and hypoperfusion. A similar loss of
the beneficial effect on collateral blood flow and infarct size
was found with excessive nitroglycerin-induced hypotension
(25). Also using a conscious dog model of left anterior
descending coronary artery occlusion, Daniell et al. (24)
studied the effect of two doses of intravenous captopril (0.25
and 0.5 mg/kg per h, respectively) between 10 min and 15 h
after occlusion and found no effect on infarct size. The
diastolic pressure in the high dose group averaged about
70 mm Hg after 4 h in that study (24). In addition, mean
arterial pressure between 1 and 12 h in that study had
decreased by 19% (from 107 to 87 mm Hg) with the low dose
and by 18% (from 96 to 79 mm Hg) with the high dose. It is
possible that this degree of hypotension might have exerted
a negative effect.
Previous studies in the rat model. In the rat model of
coronary ligation and infarction of moderate size, Pfeffer et
al. (13) studied the effect of prolonged captopril therapy
(2 g/liter of drinking water) during the healing period and
after (2 days to 3 months), and after healing (21 days to 3
months). They (13) demonstrated that captopril decreased
left ventricular filling pressure (preload), mean arterial pres-
sure (afterload) and total peripheral resistance, maintained
stroke output, decreased left ventricular volumes and nor-
malized left ventricular stiffness. In another study, Pfeffer et
al. (26) administered captopril14 days after coronary ligation
in the rat and demonstrated marked improvement in 1 year
survival. In a subsequent study from the same group (27)
with captopril given between 3weeks and 3months in the rat
model, an increase in the ejection fraction index was noted.
Raya et al. (11) emphasized, in studies with the rat model,
that captopril is not only a potent arterial vasodilator but also
a potent venodilator that increases venous compliance and
decreases blood volume, filling pressure and end-diastolic
volume.
Previous studies in humans. Several clinical studies (28-
30) have recently demonstrated beneficial effects ofcaptopril
therapy on postinfarction remodeling. Sharpe et al. (28)
showed that captopril therapy begun 1week after anterior or
inferior Q wave infarction in asymptomatic patients was
associated with prevention of left ventricular dilation and
improved ejection fraction from 1 month onward compared
with findings in furosemide and placebo groups. Pfeffer et al.
(29) also showed attenuation of left ventricular enlargement
and improved exercise tolerance in patients with a first
anterior Q wave myocardial infarction who received capto-
pril treatment starting 11 to 31 days after infarction. Re-
cently, captopril given between 2 days and 6 weeks after a
first anterior Qwave myocardial infarction was shown (30) to
preserve left ventricular geometry and function up to 1year.
Mechanisms ofcaptopril's beneficial effect. The findings in
this study suggest that the beneficial effects ofcaptopril were
primarily due to left ventricular unloading as a result of
vasodilation of arterial and venous vascular beds. Captopril
administration was begun long after completion ofthe infarc-
tion process. Both infarct scar size and transmurality were
similar in the placebo and captopril groups. It is possible that
captopril might have provided increased nutrient flow to the
healing infarct zone and adjacent myocardium. Captopril
had no adverse effect on collagen deposition or hypertrophy
of normal myocardium. Evidence of significant angiotensin-
converting enzyme inhibition with captopril was present.
The level of angiotensin II, a potent systemic and coronary
vasoconstrictor, was also likely reduced in the captopril
group. Whether angiotensin-converting enzyme inhibition
was associated with sufficient inhibition of bradykininase
activity to elevate bradykinin levels and explain the vasodi-
lator effects (31) is not known. Whether prostaglandins might
have contributed in the vasodilator responses (32) is also not
known. Nevertheless, there was evidence of significant and
sustained arterial and venous dilation with captopril in this
study. The decrease in preload, afterload and left ventricular
chamber size was probably associated with decreased left
ventricular wall stress and tension (by virtue of the Laplace
law) and less topographic deformation (12). The decrease in
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rate-pressure product and myocardial oxygen demands
might also have contributed in the healing process. Similar
mechanisms with nitroglycerin therapy were associated with
beneficial effects on collateral blood flow (25,33), infarct size
(7,8,25,33) and remodeling (7,8,30).
Conclusions. Angiotensin-converting enzyme inhibition
and left ventricular angiotensin-converting enzyme unload-
ing with captopril during healing after infarction were effec-
tive in preventing progressive remodeling and interrupting
the vicious cycle of more expansion, thinning, dilation and
aneurysm formation in the canine model. Several clinical
studies (8,12,15,16,19,34) have indicated that survivors of
anterior transmural acute myocardial infarction are at in-
creased risk for expansion and topographic deterioration.
Captopril (27-30) and enalapril (35) have been suggested as
promising agents to prevent progressive left ventricular
dilation and dysfunction after infarction. The results of this
pathophysiologic study and others suggest that application
of therapy early after infarction and throughout the healing
phase (and perhaps even after) might be most effective in
preserving left ventricular geometry and function.
We are grateful to John Henriksen for technical assistance with surgery,
Blaine Blinston and Gordon Blinston, PhD for computing and statistics and
Catherine Jugdutt and Emilia Vitelar for secretarial assistance.
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